

CLAIMS

9. (currently amended) The composition according to claim 1 , wherein [A method of prolonging] the half-life of a fibrinolytic agent is prolonged by administering an effective amount of anti-LRP antibodies [and a fibrinolytic agent] to induce the desired level of fibrinolytic activity without causing hemorrhage.

10. (currently amended) The [[method]] composition according to claim 9, wherein the fibrinolytic agent comprises scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA-derivatives, reteplase, lanoteplase, TNK-rt-PA, rt-PA derivatives, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative.